Max Healthcare Reports 20% YoY Revenue Growth in Q2
- MAXHEALTH reported Q2 FY27 revenue of ₹3,219 crore, registering approximately 20% year-on-year growth. - Profit after tax (PAT) stood at ₹448 crore, up 10% year-on-year, according to the company's earnings announcement. - The company continues to expand its hospital network and capacity. - CLSA maintained an Outperform rating on the stock with a target price of ₹1,160 on November 4, 2026. Additional Update: Reuters reported a 15.6% decline in consolidated net profit, citing higher tax expenses and the absence of a previous year's one-time tax benefit. Reuters Overall Stock View Fundamental outlook: Positive, supported by increasing bed capacity, strong patient demand and improving hospital occupancy. Key factors to monitor: Consolidated profitability, expansion-related expenditure and debt levels. Stock Outlook: Revenue growth remains encouraging, but investors should monitor profitability and margins.



















